Clinical trial NCT04343859: A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Official title: A Phase I Clinical Trial of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Malignant Neoplasms
Lead sponsor: Tianjin Chasesun Pharmaceutical Co., LTD
Sponsor class: INDUSTRY
First posted: 2020-04-13
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Phase I study of IMMH-010 in patients with advanced malignant solid tumors

Detailed description: To evaluate the safety and tolerability of single-dose and multi-dose IMMH-010 in patients with advanced solid tumors, et al.

Eligibility criteria: Inclusion Criteria:

Subjects are eligible only if they meet all the following criteria:

1. Age ≥ 18 years when they sign the informed consent form;
2. Patients with advanced or metastatic solid tumors that are confirmed by cytological or histological examination, who did not respond to standard treatment regimens, or did not tolerate these regimens, or had no effective standard treatment regimens, or refused standard treatment regimens;
3. The ECOG score is 0 or 1 point (see the scoring criteria in Appendix 1);
4. Based on RECIST 1.1 (see the scoring criteria in Appendix 4), Subjects in Part B study must have at least one measurable lesion, and subjects in Part A study may have no measurable lesion;

   Definition of measurable lesion:
   1. Tumor lesion: The size must be accurately measurable on two mutually perpendicular diameters, and both diameters must be ≥10 mm or ≥2 times of the slice thickness
   2. Lymph node lesion: The size must be accurately measurable on two mutually perpendicular diameters, and both diameters must be ≥15 mm or ≥2 times of the slice thickness
5. In subjects who had received other treatments, the toxic and side effects should return to grade ≤ 1 or to the baseline (NCI-CTCAE 5.0, excluding alopecia);
6. The expected survival time should be at least 3 months;
7. Subjects should have appropriate organ and bone marrow functions, and have laboratory test results within the following ranges before entering the group:

   Bone marrow reserve (within 14 days, no transfusion of blood or blood products, or no correction by G-CSF or other hematopoietic stimulate factors): absolute neutrophils count (ANC) ≥1.5×109/L; hemoglobin (HB) ≥90 g/L; and platelet (PLT) ≥75×109/L; Liver function: ALT≤2.5×ULN; AST≤2.5×ULN; ALP≤2.5×ULN; TBIL≤1.5×ULN (patients with known Gilbert's disease are eligible if their serum bilirubin level ≤3×ULN; and patients with metastases to liver are eligible if their ALT≤5×ULN, AST≤5×ULN, and ALP≤5×ULN); and albumin ≥3 g/dL; Kidney function: creatinine ≤1.5×ULN or creatinine clearance ≥45 mL/min as calculated according to Cockcroft-Gault formula (refer to Appendix 2); Blood coagulation function: INR, PT, and APTT≤1.5×ULN (in patients not on anticoagulants; and it is decided by investigators whether patients on anticoagulants are eligible); Cardiac enzymes CK and CKMB measures are not exceeding the upper limit of normal value; Thyroid function measures are within the normal range or mildly abnormal but requiring no treatment.
8. Fertile eligible patients (males and females) must give their consent to taking reliable contraceptive measures (hormone, barrier, or sexual abstinence) throughout the trial and at least 4 months after the last dosing; reproductive-age females must have negative blood or urine pregnancy test within 21 days prior to initial dosing;
9. The subjects must give their informed consent for the study and signed ICF voluntarily before the trial;
10. The subjects or the statutory agents should be able to communicate well and complete the study complying with the protocol.

Exclusion Criteria:

Subjects are excluded if they meet one of the following exclusion criteria.

1. Subjects with a past history of pulmonary fibrosis or interstitial pneumonia, including pneumoconiosis or radiation fibrosis of lung beyond the exposure field, which is clinically significant as judged by the investigators;
2. Subjects who have received systemic glucocorticoid or any immunosuppressive agents for some condition within 14 days prior to the initial dosing, excluding local glucocorticoid via nose spray, aspiration, or other route, or systemic glucocorticoid at a physiological dose (namely not exceeding 10 mg/d of prednisone or an equivalent dose of other glucocorticoids); corticosteroids are allowed in subjects for pretreatment for venous contrast agent allergic reaction (scanning-relevant) in the study period, but it should be recorded.
3. Subjects who are expected to receive other systemic antineoplastic treatments in the study period;
4. Subjects with risks of intestinal obstruction or intestinal perforation, such as a history of diverticulitis, intra-abdominal abscess, active ulcer, GI tract obstruction, or abdominal cancer;
5. Subjects who are diagnosed with other malignant tumors within 5 years prior to the initial dosing, excluding eradicated basal cell carcinoma of skin, squamous cell carcinoma of skin, and / or radically resected in situ cancer;
6. Subjects who ever received any organ transplants, including allogeneic stem cell transplantation, but excluding those requiring no immunosuppression (such as corneal transplant and hair transplant);
7. Subjects with active metastasis to CNS and / or carcinomatous meningitis (including leptomeningeal carcinomatosis) with clinical symptoms or requiring intervention, which is unsuitable for the subjects to enter the group as judged by the investigators;
8. Subjects with active autoimmune diseases in the past 1 year and consequently requiring systemic treatments (namely systemic steroids or immunosuppressive agents);
9. Dysphagia affects oral dosing;
10. Subjects with refractory third lacunar effusion, such as massive pleural effusion and ascites;
11. Subjects with gastrointestinal disorders that might affect drug absorption (such as Crohn's disease, ulcerative colitis, and subtotal gastrectomy);
12. Subjects who received any immune checkpoint blockade therapy within 4 weeks or 5 drug half-lives (the shorter duration shall prevail), or the following immune-related adverse events (irAE) have occurred during the course of previous immunotherapy:

    a) Grade ≥3 immune-associated pneumonia; b) Grade ≥2 immune-related myocarditis;
13. Subjects who received major surgery within 4 weeks prior to the initial dosing or those whose wound did not completely heal yet; or subjects who received \>30 Gy of chest radiotherapy within 6 months prior to the initial dosing;
14. Subjects with a history of myocarditis, myocardial infarction, cerebrovascular accident, or NHYA≥2 congestive cardiac failure within 6 months prior to the initial dosing; or subjects with uncontrollable angina, unstable angina, or uncontrollable arrhythmia;
15. Subjects who received other investigational drugs within 14 days or 5 half-lives (the longer duration shall prevail) prior to the initial dosing;
16. Subjects who were vaccinated with live vaccines within 30 days prior to the initial dosing, and live-virus-free influenza vaccines are allowed;
17. Subjects with active infections requiring systemic treatments (antibiotics); or subjects who meet any one of the following criteria:

    1. Subjects positive for human immunodeficiency virus (HIV) or with a known history of acquired immune deficiency syndrome
    2. Subjects with infection of hepatitis B virus (HBV) or hepatitis C virus (HCV) (definition: HBsAg-positive and HBV DNA copy number exceeding ULN, or HCV-Ab-positive);
    3. Subjects with active tuberculosis (with an exposure history or positive tuberculosis test, and with clinical and / or imaging manifestations).
    4. Subjects positive for treponema pallidum antibody.
18. Subjects with a history of serious hypersensitivity reaction of drug;
19. Pregnant or breast-feeding women;
20. Subjects who were ineligible to participate in clinical trials as judged by the investigators.

Primary outcomes:
measure: Dose-limiting toxicity (DLT)
timeFrame: Part A Dose escalation study at the end of Cycle 1 (Cycle1 is 21 days)
measure: Adverse reaction rate
timeFrame: From date of singing informed consent until the 30 days after the last study dose or the start date of a new anti-cancer therapy, whichever came first.
Secondary outcomes:
measure: Cmax
timeFrame: Part A Dose escalation study: At the end of Cycle1(Cycle1 is 21 days), Part B: At the end of Cycle0(Cycle0 is 4 days).
measure: Tmax
timeFrame: Part A Dose escalation study: At the end of Cycle1(Cycle1 is 21 days), Part B: At the end of Cycle0(Cycle0 is 4 days).
measure: AUC
timeFrame: Part A Dose escalation study: At the end of Cycle1(Cycle1 is 21 days), Part B: At the end of Cycle0(Cycle0 is 4 days).
measure: Objective response rate (ORR)
timeFrame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first (up to approximately 2 years).
measure: Duration of response (DOR)
timeFrame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first (up to approximately 2 years).
measure: Disease control rate (DCR)
timeFrame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first (up to approximately 2 years).
measure: Progression-free survival (PFS)
timeFrame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first (up to approximately 2 years).
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangdong Provincial People's Hospital
Study officials:
affiliation: Guangdong Provincial People's Hospital
name: Yilong Wu
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jiang J, Zou X, Liu Y, Liu X, Dong K, Yao X, Feng Z, Chen X, Sheng L, Li Y. Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies. Front Pharmacol. 2021 Jun 21;12:677120. doi: 10.3389/fphar.2021.677120. eCollection 2021.